Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series

Petrelli, Fausto; Coinu, Andrea; Borgonovo, Karen; Cabiddu, Mary; Ghilardi, Mara; Lonati, Veronica; Barni, Sandro

doi:10.1016/j.clgc.2014.10.006

Cited by 22 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 , 24 , 26 , 28 Similar poor results with enzalutamide were described in a pooled analysis of ten retrospective case series of 536 patients treated with enzalutamide following progression on docetaxel and abiraterone. 31 Overall, the pooled PSA response rate ≥50% was 22.9% (95% CI: 19.3–27.1) in the whole group, 26%–34% among abiraterone responders, and 13%–20% among abiraterone-refractory patients. Median PFS was 3.1 months (range 1.4–4.9), and median OS was 8.3 months (range 2.85–10.6).…”

Section: Safety and Efficacy Studiesmentioning

confidence: 89%

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

Rodríguez‐Vida¹,

Galazi²,

Rudman³

et al. 2015

DDDT

View full text Add to dashboard Cite

In recent years, several nonhormonal and hormonal agents, including enzalutamide, have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on the basis of improved overall survival in prospective clinical trials. The incorporation of these agents has revolutionized the treatment of CRPC but has also raised the question of what is the ideal sequence of administering them. Enzalutamide is a nonsteroidal second-generation antiandrogen that has been approved for the treatment of metastatic CRPC both in the post-docetaxel and chemotherapy-naïve settings. This article reviews the pharmacological characteristics of enzalutamide, the efficacy studies which led to its approval, its safety profile, and quality of life-related parameters as well as its place in the sequential treatment and management of metastatic prostate cancer.

show abstract

Section: Safety and Efficacy Studiesmentioning

confidence: 89%

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

Rodríguez‐Vida¹,

Galazi²,

Rudman³

et al. 2015

DDDT

View full text Add to dashboard Cite

show abstract

“…There is also some evidence from a number of small retrospective cohort studies suggesting limited activity of these agents when used in a sequential fashion either before or after docetaxel chemotherapy in advanced CRPC [20][21][22][23][24][25][26][27][28][29][30]. Development of predictive biomarkers to facilitate the selection of patients for a specific therapy or sequence of therapies is the focus of ongoing efforts.…”

Section: Discussionmentioning

confidence: 99%

Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison

Chopra¹,

Georgieva

Lopes

et al. 2017

Prostate

View full text Add to dashboard Cite

show abstract

“…The trials of abiraterone and enzalutamide excluded patients treated with the other novel AR pathway inhibitor, and abiraterone and enzalutamide were either not available or only available as part of clinical trials when the trials of docetaxel, sipuleucel-T, radium-223 and cabazitaxel were conducted. Evidence from a number of small retrospective cohort studies suggests limited activity from whichever of abiraterone and enzalutamide are used second in a sequential fashion [49][50][51][52][53]. Docetaxel after one or both of newer AR pathway inhibitors may have less activity than in the pivotal trials [54][55][56].…”

Section: Treatment Choice and Sequencing For Men With Metastatic Crpcmentioning

confidence: 99%

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Gillessen¹,

Omlin²,

Attard³

et al. 2019

Annals of Oncology

View full text Add to dashboard Cite

advanced prostate cancer (APC) management. The successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment choices, sequence of treatment options and appropriate patient selection. Management recommendations based on expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.

show abstract

Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series

Cited by 22 publications

References 32 publications

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer

Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Contact Info

Product

Resources

About